ViAn Therapeutics is developing an antiangiogenic peptidic drug for topical application in high-impact retinal diseases (DR, DME, AMD). Besides the non-invasive administration, this drug can stabilize retinal vasculature by impairing multiple proangiogenic signaling pathways in the endothelial cells in the capillaries. This is advantageous compared to the current anti-VEGF therapies based on antibodies that target a single soluble factor, and patients eventually develop resistance. We have preclinical proof of efficacy and early PK and Tox data supporting this is a good candidate, and we plan to get an IND in about a year.